Advertisement

 

 

Cost-effectiveness of posaconazole in private and public Brazilian hospitals.

Cost-effectiveness of posaconazole in private and public Brazilian hospitals.
Author Information (click to view)

Tuon FFB, Lino Florencio K, da Cunha CA, Lopes Rocha JL,


Tuon FFB, Lino Florencio K, da Cunha CA, Lopes Rocha JL, (click to view)

Tuon FFB, Lino Florencio K, da Cunha CA, Lopes Rocha JL,

Advertisement

Revista iberoamericana de micologia 2018 03 28() pii S1130-1406(18)30013-5
Abstract
BACKGROUND
Posaconazole is used for the prophylaxis of invasive fungal disease (IFD). Previous studies have shown it to be cost-effective compared to fluconazole/itraconazole. However, posaconazole has never been economically evaluated in developing countries.

AIMS
The aim of the present study was to perform a cost-effectiveness analysis of posaconazole compared to fluconazole in public (SUS) and private hospitals (PHS) in Brazil.

METHODS
A cost-effectiveness simulation was conducted on the basis of a pivotal study on the use of posaconazole in acute myeloid leukemia (AML) patients, adjusting the costs to Brazilian data.

RESULTS
A pharmacoeconomic analysis was performed on a hypothetical sample of 100 patients in each drug group. The total cost of posaconazole use alone was USD$ 220,656.31, whereas that for fluconazole was USD$ 83,875.00. Our results showed that patients with IFD remain hospitalized for an additional 12 days, at an average cost of USD$ 850.85 per patient per day. The total money spent by PHS for 100 patients for 100 days was USD$ 342,318.00 for the posaconazole group and USD$ 302,039.00 for the fluconazole group. An analysis of sensitivity (10%) revealed no intergroup difference.

CONCLUSIONS
In Brazil posaconazole is cost-effective, and should be considered for the prophylaxis of patients with AMD/myelodysplasia (AML/MDS) undergoing chemotherapy.

Submit a Comment

Your email address will not be published. Required fields are marked *

2 × 4 =

[ HIDE/SHOW ]